Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.

Oster, Wolfgang; Herrmann, F.; Gamm, H.; Zeile, G.; Lindemann, A; Müller, Gerd; Brune, Thomas; Kraemer, H.‐P.; Mertelsmann, Roland

doi:10.1200/jco.1990.8.6.956

Cited by 143 publications

(35 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact in our study two out of the three non responder patients presented the lowest levels of pretreatment serum erythropoietin. These data are consistent also with the reports by Ludwig (1990) and Oster (1990). The findings of the present study show the effectiveness and the safety of subcutaneous administration of rHuEPO even with a lower dose respect to that demonstrated effective by intravenous route.…”

Section: Discussionsupporting

confidence: 93%

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study

Cascinu¹,

Fedeli²,

Fedeli³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

In 20 patients with cisplatin-associated anaemia (haemoglobin less than 90 gl-1), recombinant human erythropoietin was administered subcutaneously three times a week on an outpatient basis. The initial dose was 50 Units Kg-1 of body weight. If response was not achieved within 3 weeks, dose was increased to 75 Units Kg-1. Using the same criteria further escalation to 100 Units Kg-1 was performed. If there was no response erythropoietin was terminated. Fifteen patients obtained an increase in haemoglobin to above 100 gl-1 which was considered as a clinical response in this study, with a dose of 50 Units Kg-1; one patient needed an erythropoietin dose of 75 Units Kg-1 and one a dose of 100 Units Kg-1. Only three patients required haemotransfusions and were considered non responders. Haemoglobin increases occurred despite continuation of cisplatin chemotherapy. In conclusion subcutaneous low dose of erythropoietin seems to be effective and safe in the treatment of cisplatin-induced anaemia.

show abstract

Section: Discussionsupporting

confidence: 93%

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study

Cascinu¹,

Fedeli²,

Fedeli³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…These findings are in agreement with published data suggesting that in chronic lymphoproliferative disorders, anemia is not only related to the bone marrow infiltration by the neoplastic clone [23, 24]. …”

Section: Discussionsupporting

confidence: 83%

Evaluation of Tumor Necrosis Factor-α and Erythropoietin Serum Levels in B-Cell Chronic Lymphocytic Leukemia Patients with Anemia

Capalbo

Battista²,

Delia³

et al. 2002

Acta Haematol

View full text Add to dashboard Cite

Serum levels of tumor necrosis factor-α (TNF-α) and of erythropoietin (Epo) have been evaluated in 100 patients with B-cell chronic lymphocytic leukemia (CLL) in order to determine whether these factors could be significant in the development of anemia, which was observed in some cases with advanced disease. In our series of patients, TNF-α serum levels had an inverse correlation with hemoglobin levels (r = –0.813). In patients with anemia, the serum levels of TNF-α were significantly higher (p = 0.022) than in those without anemia (186.7 ± 84.7 vs. 39.8 ± 20.7 pg/ml). Serum Epo levels were also significantly (p = 0.0003) increased in CLL patients with anemia compared to those without (134.1 ± 225.9 vs. 12.3 ± 4.8 mU/ml). The ratio of observed/predicted (O/P) serum Epo was adequate (>0.8) for the degree of anemia in 70% of patients with anemia and inadequate in the remaining 30%. In the latter, the mean serum TNF-α level was significantly higher (p = 0.005) than the mean for the anemic cases with an adequate O/P ratio of serum Epo (234.1 vs. 166.4 pg/ml). These data suggest that although CLL anemia is not characterized by inadequate Epo production, in some CLL patients this factor may be correlated. In these cases, the levels of TNF-α were significantly higher than in other anemic cases. Compared to other CLL patients with anemia, these CLL patients might better respond to therapy with recombinant human Epo in pharmacological doses.

show abstract

“…Chronic administration at 3 !Jg/ kg/ day for up to nine weeks did not sustain the increase in four of five patients. Vadhan-Raj et al (64) reported similar results when giving recombi-nant human GM-CSF by continuou s intravenous infusion for 28 days as two 14 day cycles with a two week rest interval. One patient in U1e first study progressed to acute leukemia after two doses of recombinant human GM-CSF.…”

supporting

confidence: 59%

The Potential Role of Recombinant Hematopoietic Colony‐Stimulating Factors in Preventing Infections in the Immunocompromised Host

Rusthoven

1990

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

. The potential role of recombinant hematopoietic colony-stimulating factors in preventing infections in the immunocompromised host . Can J Infect Dis 1991;2(2):74-88. Hematopoie ti c colony-stimu lating fac tors coordinate th e prolifera tion a nd maturation of bone marrow a nd periph era l blood cell s during norma l hematopoiesis . Most of these factors a re now avai lable as reco mbinant human colony-stimulating factors, a nd preclini cal a nd clin ical testing is proceeding ra pid ly. Granulocyte and granulocyte/ macrophage colony-stimulating factors ha ve been lhe mos l exten s ive ly stud ied to da le. In huma n cl inical trials. gran ulocyte colony-stimula ting fac tor improves n eutrophil counts and fun c tion . redu ces episod es of febrile n eutropenia, improves neutroph il recovery a fte r d isease-or treatment-induced myelosuppression. a nd reduces the number of serious infec tions in several ne utropenic disease stales. Granu locyte/macrophage co lony-s timula ting fac lor has s imila r biologica l properties but m ay also improve eosinophil prolifera tion a nd function. a nd pla telet ce ll recovery after myelotoxi c bon e m arrow injury. lnlerl eu!Gn -1 boosls th e effects of granu locyte colonys timulatin g fa cto r a n d granulocyte/ m acrophage colony-s timu lating faclor. but also m ay promote the resolu tion of established infec tion s in conjunc tion with a ntibiotics. The th era p eutic realiti es and fu ture thera peu tic implications of these agents for the th erapy of infectio n s, cancer and h emopoie tic disord ers a re d iscussed . Key Words: CoLony-stimuLa ting .factors. Feb rile neutropenia. H ematopoies is. NeutropeniaRole potentiel des facteurs recombinants stimulant les colonies hematopo"ietiques dans Ia prevention des infections chez l'hote immunodeprime RESUME: Les fac teu rs s timula nt les co lon ies h em atopoletiqu es coo rd onnent Ia prolifera tion et la m atura tion des ce llul es de Ia m oell e osseuse et du sang periph e riqu e a u cours de l' hematopolese nor mal e. La plupa rl de ces facleurs co nn us sou s le nom de "facteurs sti mul a nt les colonies" font acluell emen t l'obj e l d'evalua tion s precliniqu es e t cliniques qui progressenl

show abstract

Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.

Cited by 143 publications

References 12 publications

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study

Evaluation of Tumor Necrosis Factor-α and Erythropoietin Serum Levels in B-Cell Chronic Lymphocytic Leukemia Patients with Anemia

The Potential Role of Recombinant Hematopoietic Colony‐Stimulating Factors in Preventing Infections in the Immunocompromised Host

Contact Info

Product

Resources

About